[May 20, 2021] Medpacto releases two abstracts related to Vactosertib at ASCO annual meeting

Medpacto releases two abstracts related to Vactosertib at ASCO annual meeting [May 20, 2021] Medpacto (CEO, Seong-jin Kim) published an abstract on the clinical data for colorectal cancer and multiple myeloma in the American Society of Clinical Oncology (ASCO). The first abstract is the result of co-administration of Vactosertib and Keytruda in 33 patients with microsatellite stable (MSS) type colorectal cancer. Medpacto revealed that it recorded an objective response rate (ORR) of 15.2% in phase 1b/2a clinical trials. This is data obtained from a group of patients whose response rate is close..........

원문링크 : [May 20, 2021] Medpacto releases two abstracts related to Vactosertib at ASCO annual meeting